Sight Sciences, Inc.

SGHT Nasdaq CIK: 0001531177

Company Information

Industry Surgical & Medical Instruments & Apparatus
SIC Code 3841
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 4040 CAMPBELL AVE,, MENLO PARK, CA, 94025
Mailing Address 4040 CAMPBELL AVE,, MENLO PARK, CA, 94025
Phone (415) 889-0550
Fiscal Year End 1231
EIN 800625749

Financial Overview

FY2025

$142.84M
Total Assets
$120.36M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report April 3, 2026 View on SEC
4 Insider stock transaction report April 3, 2026 View on SEC
4 Insider stock transaction report April 3, 2026 View on SEC
4 Insider stock transaction report April 3, 2026 View on SEC
8-K Current report of material events March 30, 2026 View on SEC
8-K Current report of material events March 4, 2026 View on SEC
10-K Annual financial report March 4, 2026 View on SEC
4 Insider stock transaction report February 23, 2026 View on SEC
4 Insider stock transaction report February 5, 2026 View on SEC
4 Insider stock transaction report February 5, 2026 View on SEC

Annual Reports

10-K March 4, 2026
  • Achieved robust 50% revenue growth in 2025, reaching $75 million, driven by OMNI and TearCare systems.
  • Demonstrated strong financial health with a 70% gross margin and an improving net loss trend ($30M vs $45M prior year).
View Analysis

Material Events

8-K Legal Issue March 30, 2026
High Impact
  • Federal court ruled Alcon willfully infringed on Sight Sciences' OMNI patents.
  • Awarded $34 million in damages plus a 10% royalty on future U.S. Hydrus sales.
View Analysis

Insider Trading

STRONG SELL 7 insiders 21 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 3841)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.